Transarterial Chemoembolization in Hepatocellular Carcinoma, Albanian Experience.
AJTES Vol 6, No 2, July 2022
Laçi I et al - Transarterial Chemoembolization in Hepatocellular Carcinoma, Albanian Experience.

Keywords

hepatocellular carcinoma
chemoembolization
transcatheter therapy
TACE

How to Cite

Laçi, I., & Spahiu, A. (2022). Transarterial Chemoembolization in Hepatocellular Carcinoma, Albanian Experience. Albanian Journal of Trauma and Emergency Surgery, 6(2), 1053 -1060. https://doi.org/10.32391/ajtes.v6i2.291

Abstract

Liver cancer is the sixth most common cancer worldwide in terms of the number of cases (626,000 or 5.7% of new cancer cases) but due to the very poor prognosis, the number of deaths is nearly similar (598,000). The survival rate is 3% to 5% in cancer registries for the United States and developing countries. The modality of treatment in hepatocellular carcinoma (HCC) patients depends on the stage of the disease. The Barcelona Clinic Liver Cancer Classification (BCLC) is the favorite staging system. There are many patients who initially present with the intermediate-stage disease, and in this setting transarterial chemoembolization (TACE) is the treatment of choice.

The purpose of this article is to highlight and discuss the role of chemoembolization in the treatment of hepatocellular carcinoma, including the results of recent large studies, and the concept of combined therapies, illustrating our case.

The differences in individual factors that are not captured by the BCLC framework, such as the tumor growth pattern, degree of hypervascularity, and vascular supply, complicate the further evaluation of these patients. Because of these differences, not all patients benefit equally from TACE. Several tools have been devised to aid the decision-making process which have shown promising initial results but have failed external evaluation and have not been translated to the clinical aspects. Criteria for treatment decisions in daily clinical practice are needed in all stages of the disease.

Conclusion: TACE is a safe method for prolonging patients' survival with unresectable HCC. The correct treatment of HCC is concentrated in cancer centers, and cooperation between multiple specialists is necessary.

https://doi.org/10.32391/ajtes.v6i2.291
Laçi I et al - Transarterial Chemoembolization in Hepatocellular Carcinoma, Albanian Experience.

References

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12. Erratum in: CA Cancer J Clin. 2020 Jul;70(4):313. PMID: 30207593.

World Health Organization (WHO) (2020) Global Health Estimates 2020: Deaths by Cause, Age, Sex, by Country and by Region, 2000-2019. World Health Organization, Geneva.

http://who.int/data/gho/data/themes/mortality-and-global-health-estimates/ghe-leading-causes-of-death

Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR, Alfano CM, Jemal A, Kramer JL, Siegel RL. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 2019 Sep;69(5):363-385. doi: 10.3322/caac.21565. Epub 2019 Jun 11. PMID: 31184787.

Parkin D M, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74–108. [PubMed] [Google Scholar]

Petrick JL, Florio AA, Znaor A, Ruggieri D, Laversanne M, Alvarez CS, Ferlay J, et al. International trends in hepatocellular carcinoma incidence, 1978–2012. Int J Cancer 2019; E-pub (Oct 10). [Google Scholar] [Ref list]

Valery PC, Laversanne M, Clark PJ, Petrick JL, McGlynn KA, Bray F. Projections of primary liver cancer to 2030 in 30 countries worldwide. Hepatology 2018;67:600–611. [PMC free article] [PubMed] [Google Scholar] [Ref list]

Golabi P, Fazel S, Otgonsuren M, Sayiner M, Locklear CT, Younossi ZM. Mortality assessment of patients with hepatocellular carcinoma according to underlying disease and treatment modalities. Medicine (Baltimore) 2017;96:e5904. [PMC free article] [PubMed] [Google Scholar] [Ref list]

McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of Hepatocellular Carcinoma. Hepatology. 2021 Jan;73 Suppl 1(Suppl 1):4-13. doi: 10.1002/hep.31288. Epub 2020 Nov 24. PMID: 32319693; PMCID: PMC7577946.

Simonetti RG, Cammà C, Fiorello F, Politi F, D’ Amico G, Pagliaro L. Hepatocellular carcinoma. A worldwide problem and the major risk factors. Dig Dis Sci. 1991;36(7):962–972. [PubMed] [Google Scholar] [Ref list]

Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet. 1981;2(8256):1129–1133. [PubMed] [Google Scholar] [Ref list]

Hassan MM, Hwang LY, Hatten CJ, et al. Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus. Hepatology. 2002;36(5):1206–1213. [PubMed] [Google Scholar] [Ref list]

Sugano S, Miyoshi K, Suzuki T, Kawafune T, Kubota M. Intrahepatic arteriovenous shunting due to hepatocellular carcinoma and cirrhosis, and its change by transcatheter arterial embolization. Am J Gastroenterol. 1994;89(2):184–188. [PubMed] [Google Scholar] [Ref list]

Uka K, Aikata H, Takaki S, et al. Clinical features and prognosis of patients with extrahepatic metastases from hepatocellular carcinoma. World J Gastroenterol. 2007;13(3):4l4–420. [PMC free article] [PubMed] [Google Scholar] [Ref list]

B. Resuli, S. Prifti, B. Kraja, et al. Epidemiology of hepatitis B virus infection in Albania. World J Gastroenterol 2009; 15(7): 849-852.

Turati F, Trichopoulos D, Polesel J, Bravi F, Rossi M, Talamini R, et al. Mediterranean diet and hepatocellular carcinoma. J Hepatol 2014;60:606-11

Polesel J, Talamini R, Montella M, Maso LD, Crovatto M, Parpinel M, et al.Nutrient intake and the risk of hepatocellular carcinoma in Italy. Eur J Cancer 2007;43:2381-7

Ferlay J, Soerjomataram I, Dikshit R et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136:E359-E386.

Bashkim Resuli, Agim Sallaku, "Hepatocellular Carcinoma in Albania: Incidence and Risk Factors", International Journal of Science and Research (IJSR), Volume 5 Issue 1, January 2016, pp.1178 1183, https://www.ijsr.net/get_abstract.php?paper_id=NOV152992

Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004;130(7):4l7–422. [PubMed] [Google Scholar] [Ref list]

Crissien AM, Frenette C. Current management of hepatocellular carcinoma. Gastroenterol Hepatol (N Y). 2014 Mar;10(3):153-61. PMID: 24829542; PMCID: PMC4014047.

Wald C, Russo MW, Heimbach JK, Hussain HK, Pomfret EA, Bruix J. New OPTN/UNOS policy for liver transplant allocation: standardization of liver imaging, diagnosis, classification, and reporting of hepatocellular carcinoma. Radiology. 2013;266(2):376–382. [PubMed] [Google Scholar] [Ref list]

Yu NC, Chaudhari V, Raman SS, et al. CT, and MRI improve detection of hepatocellular carcinoma, compared with ultrasound alone, in patients with cirrhosis. Clin Gastroenterol Hepatol. 2011;9(2):161–167. [PubMed] [Google Scholar] [Ref list]

Roxburgh P, Evans TR. Systemic therapy of hepatocellular carcinoma: are we making progress? Adv Ther. 2008;25(11):1089–1104. [PubMed] [Google Scholar] [Ref list]

Nordenstedt H, White DL, El-Serag HB. The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis. 2010;42(suppl 3): S206–S214. [PMC free article] [PubMed] [Google Scholar] [Ref list]

Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19(3):329–338. [PubMed] [Google Scholar] [Ref list]

Olsen A H, Parkin D M, Sasieni P. Cancer mortality in the United Kingdom: projections to the year 2025. Br J Cancer. 2008;99(9):1549–1554. [PMC free article] [PubMed] [Google Scholar]

Davis G L Alter M J El-Serag H Poynard T Jennings L W Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression Gastroenterology 20101382513–521., e1–e6 [PubMed] [Google Scholar]

Bruix J, Sherman M. American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020–1022. [PMC free article] [PubMed] [Google Scholar]

Lencioni R. Chemoembolization for hepatocellular carcinoma. Semin Oncol. 2012;39(4):503–509. [PubMed] [Google Scholar]

Llovet J M, Di Bisceglie A M, Bruix J. et al. Panel of Experts in HCC-Design Clinical Trials. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008;100(10):698–711. [PubMed] [Google Scholar]

European Association for the Study of the Liver; European Organization for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56(4):908–943. [PubMed] [Google Scholar]

Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatology. 2010;52(2):762–773. [PubMed] [Google Scholar]

Varela M, Real M I, Burrel M. et al. Chemoembolization of hepatocellular carcinoma with drug-eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol. 2007;46(3):474–481. [PubMed] [Google Scholar]

Lammer J, Malagari K, Vogl T. et al. PRECISION V Investigators. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol. 2010;33(1):41–52. [PMC free article] [PubMed] [Google Scholar]

Vogl T J, Lammer J, Lencioni R. et al. Liver, gastrointestinal and cardiac toxicity in intermediate hepatocellular carcinoma treated with PRECISION TACE with drug-eluting beads: results from the PRECISION V randomized trial. AJR Am J Roentgenol. 2011;197(4):W562–W570. [PubMed] [Google Scholar]

Lencioni R, Crocetti L. Local-regional treatment of hepatocellular carcinoma. Radiology 2012;262(1):43–58

Lencioni R, de Baere T, Burrel M, Caridi JG, Lammer J, Malagari K, Martin RC, O'Grady E, Real MI, Vogl TJ, Watkinson A, Geschwind JF. Transcatheter treatment of hepatocellular carcinoma with Doxorubicin-loaded DC Bead (DEBDOX): technical recommendations. Cardiovasc Intervent Radiol. 2012 Oct;35(5):980-5. doi: 10.1007/s00270-011-0287-7. Epub 2011 Oct 19. PMID: 22009576; PMCID: PMC3447142.

Kim HC, Chung JW, Park JH, et al. Transcatheter arterial chemoembolization for hepatocellular carcinoma: prospective assessment of the right inferior phrenic artery with C-arm CT. J Vasc Interv Radiol 2009: 20; 888-895.

Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology. 2016 Jan 12, http://dx.doi.org/10.1053/j.gastro.2015.12.041, pii: S0016-5085(16)00007-X [Epub ahead of print].

Piscaglia F., Ogasawara S. Patient Selection for Transarterial Chemoembolization in Hepatocellular Carcinoma: Importance of Benefit/Risk Assessment. Liver Cancer. 2018;7:104–119. doi: 10.1159/000485471. [PMC free article] [PubMed] [CrossRef] [Google Scholar] [Ref list]

.315. Raoul J, Sangro B, Forner A, Mazzaferro V, Piscaglia F, Bolondi L, et al. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev. 2011;37:212–20.

Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet.2002;359:1734–9.

Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35:1164–71

Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology.2003;37:429–42.176.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.